>if actos gets the warning label, byetta and januvia may benefit but slowly.<
For Actos, it’s a matter of when, not if. Dr. von E confirmed to a Congressional committee this week that Actos will soon have a new black-box warning. However, the FDA currently lacks the authority to change the product label unilaterally, and hence the warning language must be negotiated with the vendor (Takeda in this case). Regards, Dew
p.s. Does your handle have anything to do with the former biotech company, Alpha-Beta Technology?
Market Data 
Markets 
AI
